The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Great news, reimbursement code issued and active from 1st Jan 2024
"Despite the AMA's commitment to issuing CPT codes in a timely manner it is often a difficult task for companies to navigate the process and it can take up to 2 years."
Goes to show how groundbreaking this test is
Should breach 40s today let's hope
All IMO
Nothing goes up in a straight line, still holding the 30s strongly, this will be one of those shares that just consolidates and moves up when people least expect it. It’s currently about 10/15x undervalued atm IMO
It’ll re rate
Is to partner with the leading healthcare laboratory testing companies and use their existing laboratory testing facilities and distribution networks to achieve a much larger market share." .....
this will convert billions of revenue.... MCAP: barely 80m
All IMO
"in the us market it is expected that both self-paying patients and those with medical insurance will use the test. whilst the test has been launched without a unique cpt/pla code, the company know from their cirt experience that having a unique insurance code in place enables faster and higher reimbursement rates. it is expected that the cost of the pse test for self-pay concierge patients will be $950.
in the uk the test is available through private medical practices and will cost £750. given the significant benefits the test provides it is hoped that the nhs will be able to fast track approval for the pse test to be incorporated into a national screening program – something that has been called for by health professionals and advocacy groups for a long time. "
"their current lab facility in frederick, maryland has the capacity to process 200,000 tests a year. this capacity could be tripled to 600k tests a year with further investment estimated at $1.5m. the plan though, after launch and adoption, is to partner with the leading healthcare laboratory testing companies and use their existing laboratory testing facilities and distribution networks to achieve a much larger market share."
600,000 x £750..... = £450m
600,000 of 25m in the usa and 5m in the uk......
wake up folks
**** me talk about lottery ticket?
all imo
Not unreasonable, but the 2 key things here are:
No one would be chancing a 55% routine annual test if there's a 90%+ one out there, private or not. I know which one I'm going for.
2) The market doesn't 'wait' until rollout to value a company, it's forward looking - if it can be worth multiple billions at some point it'll place a value on that
3) There's been minimal PR currently, but wait until word spreads
Will be the biggest success story on AIM
All IMO
Not even the best RNS of the year, probably in a decade..... 10x from would still be dirt cheap IMO
I've seen anywhere from $300-$1000 per test
25m from USA, 5m from UK, other countries to follow?
EpiSwitch - check out the rest of the pipeline
Just do the Math, this is unheard of in the LSE
All IMO
Going to try a less rampy projection:
The numbers quoted are around 25m in the USA and 5m in the UK tested annually
Assuming we will capture 80% of the uk considering it’s been 10 years work with NHS collab
That gives us 4m, we also lead science guidelines in global healthcare, say just 10% of the USA testing at 2.5m
Gives us 6.5m per annum, an inferior test has been quoted at 300$ earlier assuming profits are at 1/3 that’s $100 per piece
Giving us $650m or £500m in profit per annum, apply a low P/E of 3
Gives us £1.5bn/250m shares (we will need a raise at some point next year probably)
Which is £6 per share
This opportunity is unheard of, no wonder the directors are in heavy at much higher prices and this reached £2+ at one point
This is just two countries and one arm of episwitch, which o wouldn’t be surprised to see it go to big pharma for several billion
All IMO
Trust me when I say 10bag from here is selling it way short for what we have on offer, do the numbers yourself 30m per annum for two countries only, a monopoly of the market, apply profit and P/E
IMO
Data from the PROSTAGRAM NHS study, published in Cancers, a high-impact, peer-reviewed journal in February 2023, showed that PSE demonstrated compelling results of 93% positive predictive value, 95% negative predictive value and overall accuracy of 94%. The Company experienced an unprecedented level of interest in the test following the announcement of the publication of these results, both from doctors and in the mainstream media. In response, the Company has moved quickly to expedite development and commercial launch of the test.
The Company's PSE test will offer a rapid, minimally invasive, accurate test with significant potential as a screening diagnostic and large addressable markets. In the US there are approximately 47 million men aged between 50 and 74, with 25 million PSA tests performed annually (2021 figures). There are approximately 10 million men in the same age bracket in the UK.
Calling it now Episwitch goes for several billion
All IMO